Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis

Description:

Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Fluzone ID is an inactivated, trivalent influenza vaccine that is administered via intradermal injection. Fluzone ID's production is similar to other inactivated, split virus influenza vaccines, but its route of administration differentiates it from its competitors. This novel route of administration uses a needle that is 90% smaller than the one used for intramuscular injection. The site of injection (i.e., the dermis) also has an increased number of immune cells compared to muscle tissue, which results in a more robust immune response for intradermal injection relative to intramuscular route of administration. Sanofi, which distributes the vaccine in the US and Europe, hopes to leverage these advantages to obtain patient share.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fluzone IntraDermal including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fluzone IntraDermal for four countries from 2012 to 2022.
- Sales information covered for the US, France, Germany and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fluzone IntraDermal performance
- Obtain sales forecast for Fluzone IntraDermal from 2012 to 2022 in the US, France, Germany and the UK.

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis
Web Address: http://www.researchandmarkets.com/reports/2368619/
Office Code: SC6IYJJ4

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World